Abstract
Somatostatin receptor type 2 (SST2) is the main pharmacological target of somatostatin (SS) analogues widely used in patients with pancreatic neuroendocrine tumours (P-NETs), this treatment being ineffective in a subset of patients. Since it has been demonstrated that Filamin A (FLNA) is involved in mediating GPCR expression, membrane anchoring and signalling, we investigated the role of this cytoskeleton protein in SST2 expression and signalling, angiogenesis, cell adhesion and cell migration in human P-NETs and in QGP1 cell line. We demonstrated that FLNA silencing was not able to affect SST2 expression in P-NET cells in basal conditions. Conversely, a significant reduction in SST2 expression (-43±21%, P
| Original language | English |
|---|---|
| Pages (from-to) | 181-190 |
| Number of pages | 10 |
| Journal | Endocrine-Related Cancer |
| Volume | 23 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 1 2016 |
Fingerprint
Keywords
- Filamin A
- Neuroendocrine tumours
- Somatostatin
- Somatostatin receptor type 2
ASJC Scopus subject areas
- Endocrinology
- Oncology
- Cancer Research
- Endocrinology, Diabetes and Metabolism
Cite this
Filamin-a is required to mediate SST2 effects in pancreatic neuroendocrine tumours. / Vitali, Eleonora; Cambiaghi, Valeria; Zerbi, Alessandro; Carnaghi, Carlo; Colombo, Piergiuseppe; Peverelli, Erika; Spada, Anna; Mantovani, Giovanna; Lania, Andrea G.
In: Endocrine-Related Cancer, Vol. 23, No. 3, 01.03.2016, p. 181-190.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Filamin-a is required to mediate SST2 effects in pancreatic neuroendocrine tumours
AU - Vitali, Eleonora
AU - Cambiaghi, Valeria
AU - Zerbi, Alessandro
AU - Carnaghi, Carlo
AU - Colombo, Piergiuseppe
AU - Peverelli, Erika
AU - Spada, Anna
AU - Mantovani, Giovanna
AU - Lania, Andrea G.
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Somatostatin receptor type 2 (SST2) is the main pharmacological target of somatostatin (SS) analogues widely used in patients with pancreatic neuroendocrine tumours (P-NETs), this treatment being ineffective in a subset of patients. Since it has been demonstrated that Filamin A (FLNA) is involved in mediating GPCR expression, membrane anchoring and signalling, we investigated the role of this cytoskeleton protein in SST2 expression and signalling, angiogenesis, cell adhesion and cell migration in human P-NETs and in QGP1 cell line. We demonstrated that FLNA silencing was not able to affect SST2 expression in P-NET cells in basal conditions. Conversely, a significant reduction in SST2 expression (-43±21%, P
AB - Somatostatin receptor type 2 (SST2) is the main pharmacological target of somatostatin (SS) analogues widely used in patients with pancreatic neuroendocrine tumours (P-NETs), this treatment being ineffective in a subset of patients. Since it has been demonstrated that Filamin A (FLNA) is involved in mediating GPCR expression, membrane anchoring and signalling, we investigated the role of this cytoskeleton protein in SST2 expression and signalling, angiogenesis, cell adhesion and cell migration in human P-NETs and in QGP1 cell line. We demonstrated that FLNA silencing was not able to affect SST2 expression in P-NET cells in basal conditions. Conversely, a significant reduction in SST2 expression (-43±21%, P
KW - Filamin A
KW - Neuroendocrine tumours
KW - Somatostatin
KW - Somatostatin receptor type 2
UR - http://www.scopus.com/inward/record.url?scp=84963959675&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84963959675&partnerID=8YFLogxK
U2 - 10.1530/ERC-15-0358
DO - 10.1530/ERC-15-0358
M3 - Article
AN - SCOPUS:84963959675
VL - 23
SP - 181
EP - 190
JO - Endocrine-Related Cancer
JF - Endocrine-Related Cancer
SN - 1351-0088
IS - 3
ER -